Drugs / C7R.CD30.CAR-EBVST cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06176690 | Oct 2025 → Jul 2028 expected | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Hodgkins lymphoma, diffuse large B-cell lymphoma +1 | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C7R.CD30.CAR-EBVST cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06176690 ↗ |
| Modality | Cell therapy | “modified T cells include a marker called iC9” NCT06176690 ↗ |
| Route | Intravenous | “C7R.CD30.CAR-EBVST cells are administered as a single intravenous infusion” NCT06176690 ↗ |